

Article

Antarctic Krill Oil in Joint Health: Inflammatory Context and Heterogeneous Randomized Evidence

Anas Ziraoui¹, Rajesh Kumar², Rizky Saputra³

1,2,3. National Standards Laboratory SA, Chemin des Orlons 10, CH-1860 Aigle, Switzerland

Citation: Ziraoui, A., Kumar, R., Saputra, R. Antarctic Krill Oil in Joint Health: Inflammatory Context and Heterogeneous Randomized Evidence. American Journal Of Bioscience And Clinical Integrity 2026, 3(9), 14-19.

Received: 20th Jul 2026

Revised: 15th Aug 2026

Accepted: 30th Aug 2026

Published: 24th Sept 2026



Copyright: © 2026 by the authors. Submitted for open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>)

Abstract: Clinical studies of Antarctic krill oil have examined joint discomfort and inflammatory outcomes, with results differing by phenotype, dose and duration. We characterized a phospholipid-rich BCLC® krill oil prepared at low temperature under light-shielded and nitrogen-protected conditions, then considered its formulation quality alongside the human joint-health literature. In the optimized process, separable insolubles before filtration were reduced to 0.31%, and peroxide values remained at 2.5-2.7 meq/kg. Some randomized studies reported changes in inflammatory markers or knee symptoms in mild-to-moderate populations. A 2024 trial of 262 adults with knee osteoarthritis, significant pain and MRI-defined effusion-synovitis, however, found no pain benefit with 2 g/day krill oil over 24 weeks. The variation between trials points to omega-3 exposure, baseline joint pathology and dose as relevant determinants of response.

Keywords: Antarctic Krill Oil, Joint Health, Inflammation, Osteoarthritis, EPA, DHA, Phospholipids

Introduction

Clinical interest in krill oil for joint symptoms has developed alongside a broader effort to distinguish inflammatory discomfort from structurally advanced osteoarthritis. Early randomized work reported changes in C-reactive protein and arthritic symptoms in mixed inflammatory populations, while later trials focused more narrowly on knee pain, stiffness, physical function and imaging-defined disease. The findings have not been uniform: benefits were reported in mild knee pain and in mild-to-moderate osteoarthritis, whereas the KARAOKE trial found no pain advantage in participants with substantial symptoms and MRI-confirmed effusion-synovitis [1]–[4]. This spread of results makes population definition, baseline pathology, dose and treatment duration central to interpretation rather than secondary trial details.

Krill oil also differs from conventional fish-oil preparations in its lipid matrix. EPA and DHA are distributed across phospholipid and neutral-lipid fractions, and comparative work has examined how that structure affects bioavailability and lipid responses [5]–[8]. These studies do not establish a joint-specific effect by themselves, but they help explain why nominal grams of oil are an incomplete description of exposure. For a formulation intended for repeated oral use, the proportions of phospholipids and omega-3 fatty acids, together with oxidative quality, determine what is actually delivered before any clinical endpoint is considered.

The manufacturing literature adds another layer to that question. Processing strategies for highly active krill omega-3 ingredients are designed to preserve unsaturated lipids and reduce unwanted

particulate or colloidal material, while clinical syntheses show that krill-oil interventions can modify lipid-related biomarkers in some settings [9], [10]. At the same time, current inflammation research emphasizes not only the generation of pro-inflammatory eicosanoids but also the formation and resolution of lipid-mediator signals [11]. This is relevant to joint research because symptom change may depend on biological context even when omega-3 exposure is measurable.

EPA and DHA can alter the fatty-acid substrate available to inflammatory pathways, although the magnitude and clinical meaning of that shift vary by tissue, disease state and achieved exposure [12], [13]. High-dose krill-derived omega-3 has also been studied outside joint disease, including severe hypertriglyceridemia, illustrating the importance of defining the administered EPA/DHA dose [14]. Direct measurements of EPA and DHA incorporation into plasma phospholipids provide a practical way to connect formulation intake with biological exposure [15]. Those considerations support evaluating a krill-oil product at three separate levels: formulation quality, biochemical incorporation and joint-specific clinical response.

A representative optimized batch of BCLC® Antarctic krill oil contained approximately 42% total phospholipids, 7.8% EPA and 3.9% DHA. Processing also reduced separable insolubles and kept the peroxide value low. We examined the relevance of this controlled oil matrix to published human evidence on inflammation and joint health.

Formulation measurements, biomarker changes and clinical symptoms were evaluated as separate levels of evidence.

Table 1. Formulation-performance profile of optimized and comparator Antarctic krill oil preparations.

Preparation	Yield %	Phospholipid %	EPA %	DHA %	PV meq/kg	Insolubles %
Optimized 1	8.6	42.1	7.8	3.9	2.6	0.31
Optimized 2	8.5	41.8	7.7	3.8	2.7	0.33
Optimized 3	8.4	42.3	7.9	4.0	2.5	0.30
Single 75% ethanol	7.8	38.7	6.9	3.4	3.4	0.68
Single 90% ethanol	8.0	39.2	7.0	3.5	3.2	0.60
No 8°C standing	8.5	41.6	7.7	3.8	2.8	0.52

Materials and Method

Formulation-quality evaluation

The optimized oil was produced by dual-concentration extraction with food-grade ethanol. After standing at 8°C, the extract was centrifuged and membrane-filtered, concentrated at low temperature under light protection and desolventized under nitrogen. Separable insolubles before filtration were measured as an indicator of clarification. Peroxide value described oxidative quality.

Comparator conditions

Comparator oils were prepared by a single extraction with 75% ethanol, a single extraction with 90% ethanol, or by omitting the 8°C standing step. The last condition was used to examine the contribution of low-temperature flocculation and sedimentation before filtration.

Clinical evidence synthesis

We reviewed randomized studies reporting joint pain, osteoarthritis symptoms, C-reactive protein or other inflammatory outcomes. Study populations, krill-oil dose, duration, EPA/DHA

exposure and the presence of effusion-synovitis were recorded because these conditions differed across trials.

Table 2. Randomized human evidence relevant to krill oil, inflammation and joint health.

Study	Population/design	Dose/duration	Joint/inflammatory observation
Deutsch, 2007	90 people with elevated CRP and cardiovascular disease, rheumatoid arthritis and/or OA	300 mg/day krill oil, 30 days	Reported reductions in CRP and improvements in pain, stiffness and functional impairment, mixed diagnostic population.
Suzuki et al., 2016	50 adults with mild knee pain, randomized double-blind placebo-controlled	2 g/day krill oil, 30 days	Reported improvements in knee pain/stiffness, blood inflammatory markers were not materially changed.
Stonehouse et al., 2022	235 adults with mild-moderate knee OA, multicenter double-blind RCT	4 g/day krill oil, 6 months	Modest improvements in WOMAC pain, stiffness and physical function, Omega-3 Index increased.
Laslett et al., 2024	262 adults with knee OA, significant pain and MRI effusion-synovitis, multicenter RCT	2 g/day krill oil, 24 weeks	No between-group improvement in knee pain, illustrates population/dose heterogeneity.

Results

Clarification and oxidative quality

The representative optimized process produced 0.31% separable insolubles before filtration. Values were 0.68% after single 75% ethanol extraction and 0.60% after single 90% ethanol extraction. When the 8°C standing step was omitted, insolubles increased to 0.52%. Peroxide values in the optimized preparations were 2.5-2.7 meq/kg, compared with 3.4 and 3.2 meq/kg in the single-concentration controls.

Human inflammatory and joint evidence

Deutsch studied a mixed population with cardiovascular disease, rheumatoid arthritis or osteoarthritis and reported lower CRP and improved arthritic symptoms with 300 mg/day krill oil [1]. In a separate 30-day trial, Suzuki et al. found improvements in mild knee pain and stiffness with 2 g/day krill oil. Blood inflammatory markers changed little [2].

Stonehouse et al. followed adults with mild to moderate knee osteoarthritis for 6 months. Krill oil at 4 g/day produced modest improvements in pain, stiffness and physical function, and the Omega-3 Index increased [3]. The 2024 KARAOKE trial enrolled 262 adults with clinically significant pain and

MRI-detected effusion-synovitis. After 24 weeks, pain did not differ between the 2 g/day krill-oil group and placebo [4].

The doses ranged from 0.3 to 4 g/day, and the study populations ranged from mild knee pain to established osteoarthritis with effusion-synovitis. Corresponding EPA/DHA exposure also differed. The trials therefore address related but not identical clinical questions.




Figure 1. Separable insolubles before filtration across optimized and comparator preparation conditions.

Discussion

Standing at 8°C reduced the amount of separable material entering membrane filtration. Lower colloidal and particulate carryover can improve consistency during concentration and limit process conditions that promote oxidation. It is a manufacturing-quality result rather than a direct predictor of joint symptoms. Peroxide values remained low in the optimized preparations, an important consideration for an oil rich in unsaturated fatty acids.

The positive trials mainly involved mild or moderate symptoms or used the higher krill-oil dose. KARAOKE examined a different phenotype: osteoarthritis with significant pain and MRI-defined effusion-synovitis, treated with 2 g/day. Its neutral pain result helps identify baseline pathology and dose as variables that should be specified in later studies.

EPA and DHA can change the substrate available for eicosanoids and specialized pro-resolving mediators, and phospholipid association may affect tissue incorporation. Osteoarthritis symptoms also reflect cartilage, bone, synovium, neuromuscular function and central pain processing. For that reason, biochemical exposure markers should be measured alongside validated pain and function outcomes in formulation-specific studies.

Current Scope and Future Directions

A BCLC® study could stratify participants by baseline Omega-3 Index, radiographic OA grade, effusion-synovitis burden and inflammatory phenotype. EPA/DHA incorporation could then be compared with standardized WOMAC or visual-analog outcomes. This design would connect measured exposure with symptoms in clinically defined subgroups.

Conclusion

The optimized process produced phospholipid-rich krill oil with few separable insolubles and controlled peroxide values. Randomized studies have reported inflammatory or joint-related changes in some settings, while the 2024 trial in osteoarthritis with effusion-synovitis found no pain advantage over placebo. Dose, EPA/DHA exposure and baseline joint phenotype should be specified when the BCLC® oil is evaluated in subsequent clinical research.

REFERENCES

- [1] Deutsch L, "Evaluation of the effect of Neptune krill oil on chronic inflammation and arthritic symptoms," *J Am Coll Nutr.* 2007,26(1):39-48. doi:10.1080/07315724.2007.10719584. PMID:17353582.
- [2] Suzuki Y, Fukushima M, Sakuraba K, Sawaki K, Sekigawa K, "Krill Oil Improves Mild Knee Joint Pain: A Randomized Control Trial," *PLoS One.* 2016,11(10):e0162769. doi:10.1371/journal.pone.0162769. PMID:27701428.
- [3] Stonehouse W, Benassi-Evans B, Bednarz J, Vincent AD, Hall S, Hill CL, "Krill oil improved osteoarthritic knee pain in adults with mild to moderate knee osteoarthritis: a 6-month multicenter, randomized, double-blind, placebo-controlled trial," *Am J Clin Nutr.* 2022,116(3):672-685. doi:10.1093/ajcn/nqac125. PMID:35880828.
- [4] Laslett LL, Antony B, Wluka AE, et al, "Krill Oil for Knee Osteoarthritis: A Randomized Clinical Trial," *JAMA.* 2024,331(23):1997-2006. doi:10.1001/jama.2024.6063. PMID:38776073.
- [5] Cicero AFG, Rosticci M, Morbini M, Cagnati M, Grandi E, Parini A, Borghi C, "Lipid-lowering and anti-inflammatory effects of omega 3 ethyl esters and krill oil: a randomized, cross-over, clinical trial," *Arch Med Sci.* 2016,12(3):507-512. doi:10.5114/aoms.2016.59923. PMID:27279841.
- [6] N. Salem Jr. and C. N. Kuratko, "A reexamination of krill oil bioavailability studies," *Lipids Health Dis.*, vol. 13, Art. no. 137, 2014, PMID: 25156381.
- [7] S. M. Ulven and K. B. Holven, "Comparison of bioavailability of krill oil versus fish oil and health effect," *Vasc. Health Risk Manag.*, vol. 11, pp. 511–524, 2015, doi: 10.2147/VHRM.S85165.
- [8] F. Vosskötter, M. Burhop, A. Hahn, and J. P. Schuchardt, "Equal bioavailability of omega-3 PUFA from Calanus oil, fish oil and krill oil: A 12-week randomized parallel study," *Lipids*, vol. 58, no. 3, pp. 129–138, 2023, PMID: 36960737.
- [9] A. Colletti et al., "Advances in technologies for highly active omega-3 fatty acids from krill oil: Clinical applications," *Mar. Drugs*, vol. 19, no. 6, 2021, PMID: 34073184.
- [10] M. G. Kim, I. Yang, H. S. Lee, J. Y. Lee, and K. Kim, "Lipid-modifying effects of krill oil vs fish oil: A network meta-analysis," *Nutr. Rev.*, vol. 78, no. 9, pp. 699–708, 2020, PMID: 32073633.
- [11] C. N. Serhan et al., "Expert consensus report on lipid mediators: Role in resolution of inflammation and muscle preservation," *FASEB J.*, vol. 38, no. 10, Art. no. e23699, 2024, PMID: 38805158.
- [12] P. C. Calder, "Omega-3 fatty acids and inflammatory processes," *Nutrients*, vol. 2, no. 3, pp. 355–374, 2010, doi: 10.3390/nu2030355.
- [13] P. C. Calder, "Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance," *Biochim. Biophys. Acta*, vol. 1851, no. 4, pp. 469–484, 2015, PMID: 25149823.

- [14] D. Mozaffarian et al., "Effectiveness of a novel ω -3 krill oil agent in patients with severe hypertriglyceridemia: A randomized clinical trial," JAMA Netw. Open, vol. 5, no. 1, Art. no. e2141898, 2022, doi: 10.1001/jamanetworkopen.2021.41898.
- [15] J. P. Schuchardt et al., "Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations," Lipids Health Dis., vol. 10, Art. no. 145, 2011, doi: 10.1186/1476-511X-10-145.